February 26, 2026 11:01 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
India-US trade deal at risk? Trump imposes massive 126% duty on solar imports | ‘My life reflects this reality’: Shooter Tara Shahdeo recalls forced conversion amid Kerala Story 2 row | Modi begins Israel visit to boost defence, tech and strategic ties | Trump claims Pakistan PM told him he prevented 35 million deaths by stopping India-Pakistan conflict | Supreme Court's big move over Bengal SIR! Odisha, Jharkhand judicial officers allowed to complete revision process | ‘Kerala lives in harmony, film’s portrayal wrong’: Kerala High Court raps Kerala Story sequel makers | AI panic hits IT giants: Infosys, TCS, Wipro lead massive market rout as stocks sink to alarming lows | ‘No systemic risk’: Sanjay Malhotra breaks silence on ₹590 crore IDFC First Bank Limited fraud | India urges all nationals to leave Iran 'by available means' as US-Iran tension grows | India shines at BAFTA! All you need to know about Manipuri film Boong that stunned global cinema
Coronavirus Vaccine

Adar Poonawalla thanks PM Modi for decisive 'policy changes and swift financial aid' amid vaccine shortage

| @indiablooms | Apr 21, 2021, at 07:18 am

Mumbai/IBNS: Serum Institute of India (SII) CEO Adar Poonawalla has lauded the Centre's policy change in vaccination, bringing all above 18 under the mass drive and extending financial support to the vaccine manufacturers.

SII which is manufacturing Covishied, developed by Oxford University and Swedish drug giant AstraZeneca, in India has been given Rs 3,000 crore as 100 per cent advance till July, reported NDTV citing senior sources in the Finance Ministry.

A similar advance of Rs 1,500 crore has been given to Hyderabad-based Bharat Biotech, the producer of indegenous Covaxin, the report added.

"This will ensure that the two companies get necessary funding to continue and scale up production," the sources said, the report added.

Earlier, Adar Poonawalla had appealed to the Centre for funds to scale up manufacturing amid high demand of the vaccine within and outside India.

Both Bharat Biotech and SII were facing shortage of funds "to scale up production, purchase raw materials, pay staff, and make and distribute enough doses of the vaccines", stated the report.

Poonawall, on Tuesday, tweeted in appreciation of the Centre's move.

The states can now buy coronavirus vaccine doses directly from manufacturers in the "liberalised and accelerated Phase 3 strategy of COVID-19 vaccination".

.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.